The most promising #vaccine candidate isn’t always the investment most likely to deliver a successful vaccine. 💉 Anthony McDonnell and Tim Laurence explain why funders should consider the portfolio as a whole and the value of diversifying risk. https://go.cgdev.org/3TXnue6
Following the Best Science Does Not Always Make the Best Vaccine Investment
The current vaccine we have against tuberculosis (TB)—the BCG vaccine—whilst valuable, has relatively low efficacy, and as a result TB remains the deadliest infectious disease in the world, killing ab...
cgdev.org